Sialanar 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0026 
Submission of an updated RMP version 3.1 in order 
08/06/2023 
Annex II 
Based on results of the safety data generated from the 
to remove a Drug Utilisation Study (DUS). In 
addition, the safety concerns, pharmacovigilance 
activities and risk minimisation measures in the RMP 
of Sialanar are revised to be in line with the 
Guideline on good pharmacovigilance practices (GVP) 
Drug Utilisation Study  (DUS) and Pharmacovigilance 
database that did not point to outstanding safety or risk 
minimisation issues regarding the identified risks Off label 
treatment of children with mild to moderate sialorrhoea, 
and Off label use in patients below the age of 3 years due 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
to the higher susceptibility to adverse effects, and missing 
information Safety in long-term use, beyond 24 weeks the 
PRAC agreed to remove the DUS from the RMP. 
Module V – Risk management systems (Rev 2). 
Furthermore, Annex II D “Conditions or restrictions 
with regard to the safe and effective use of the 
medicinal product” was revised to delete information 
about the utilisation study from the key elements of 
the physician educational material. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
14/04/2023 
n/a 
PRAC Recommendation - maintenance 
/202209 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
II/0025/G 
This was an application for a group of variations. 
01/09/2022 
31/03/2023 
SmPC 
The SmPC section 6.3 has been updated as follows: Shelf 
life is extended from 2 to 3 years. 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
IAIN/0024 
A.1 - Administrative change - Change in the name 
13/04/2022 
31/03/2023 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
07/04/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
IAIN/0022/G 
This was an application for a group of variations. 
28/09/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0021/G 
This was an application for a group of variations. 
18/06/2021 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
R/0018 
Renewal of the marketing authorisation. 
22/04/2021 
17/06/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
/202009 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Sialanar in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IA/0020 
A.7 - Administrative change - Deletion of 
09/03/2021 
17/06/2021 
Annex II and 
manufacturing sites 
PL 
IAIN/0019 
B.II.b.2.c.2 - Change to importer, batch release 
02/12/2020 
17/06/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Including batch control/testing 
IAIN/0016/G 
This was an application for a group of variations. 
02/12/2020 
17/06/2021 
Annex II and 
PL 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
A.7 - Administrative change - Deletion of 
manufacturing sites 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
30/04/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
17/04/2020 
n/a 
PRAC Recommendation - maintenance 
/201909 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
IB/0012 
B.II.f.1.d - Stability of FP - Change in storage 
03/10/2019 
09/10/2020 
SmPC, 
conditions of the finished product or the 
diluted/reconstituted product 
Labelling and 
PL 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
03/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201903 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
IAIN/0010/G 
This was an application for a group of variations. 
24/05/2019 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
11/04/2019 
n/a 
PRAC Recommendation - maintenance 
/201809 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
T/0009 
Transfer of Marketing Authorisation 
15/03/2019 
28/03/2019 
SmPC, 
Labelling and 
PL 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008 
B.II.e.4.a - Change in shape or dimensions of the 
04/01/2019 
28/03/2019 
SmPC, 
container or closure (immediate packaging) - Non-
sterile medicinal products 
Labelling and 
PL 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
04/10/2018 
n/a 
PRAC Recommendation - maintenance 
/201803 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
12/04/2018 
n/a 
PRAC Recommendation - maintenance 
/201709 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
PSUSA/10529
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201703 
glycopyrronium (indicated for the treatment of 
severe sialorhoea) 
IAIN/0003 
A.1 - Administrative change - Change in the name 
11/05/2017 
13/04/2018 
SmPC, 
and/or address of the MAH 
Labelling and 
PL 
IB/0002 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
22/03/2017 
13/04/2018 
SmPC, 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
IB/0001 
C.I.11.z - Introduction of, or change(s) to, the 
05/01/2017 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
